Lu177PSMATherapyQualityChecker

Lu-177 PSMA Therapy Quality Checker

api radiopharmaceuticals nuclear-medicine lu-177 psma theranostics prostate-cancer
Open selection

Lu-177 PSMA Therapy Quality Checker — Quality control of Lu-177 PSMA for prostate cancer therapy

ℹ️ Utility checks critical parameters of Lu-177 PSMA:

  • Radiochemical purity (≥95%)
  • Free lutetium (≤2%)
  • Precursor residue (<0.1%)
  • Specific activity (≥20 GBq/mg)
  • Lu-177m impurity (<0.01%) — CRITICAL!

⚠️ CRITICAL: Lu-177m (T½=160 days) creates long-term radiation burden!

Lu-177 PSMA is used for metastatic prostate cancer therapy.

High specific activity is necessary for effective PSMA binding.

Usage

Lu177PSMATherapyQualityChecker.exe → demo mode (console output)

Lu177PSMATherapyQualityChecker.exe input.csv output.json → evaluate your data

Input format

BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent

Example

LU177-PSMA-THER-2026-001,99.2,0.4,0.02,50.0,5.0,80.0,5.0,0,7.4,99.99,0.0003

— WHY IS THIS NEEDED?

Lu-177 PSMA (e.g., based on PSMA-617 or I&T ligand) is breakthrough in metastatic castration-resistant prostate cancer therapy.

  • Binds to prostate-specific membrane antigen (PSMA).
  • Lu-177 emits beta particles for therapy and gamma quanta for imaging.
  • Half-life 6.65 days.
  • Requires high radiochemical purity and specific activity.

⚠️ CRITICAL:

  • Radiochemical purity ≥95% — guarantee of dose delivery to tumor.
  • Free lutetium ≤2% — free ions accumulate in bones and liver.
  • Precursor residue <0.1% — unreacted ligand competes for PSMA receptors.
  • Specific activity ≥20 GBq/mg — necessary for high contrast and efficacy.
  • Lu-177m impurity <0.01% — Lu-177m is long-lived and creates unnecessary radiation burden.
  • pH 4.5-6.5 — optimal media for Lu-PSMA complex stability.
  • Residual solvents must be minimal (<500 ppm).
  • Endotoxins <175 EU/mL — standard for parenteral drugs.
  • Sterility — MANDATORY.

Key features

  • Strict control of Lu-177m impurity characteristic of reactor production.
  • Assessment of residual precursor, critical for therapy efficacy.
  • Specific activity check for effective targeting.
  • Compliance with GMP and Pharmacopoeia requirements for Lu-177 radiopharmaceuticals.
  • Comprehensive safety check (endotoxins, sterility, pH, solvents).

Critical parameters

  • Radiochemical purity: ≥95.0%
  • Free lutetium: ≤2.0%
  • Precursor residue: <0.1%
  • Specific activity: ≥20.0 GBq/mg
  • Radionuclidic purity: ≥99.9%
  • Lu-177m impurity: <0.01%
  • Residual solvents: <500 ppm
  • pH: 4.5–6.5
  • Endotoxins: <175 EU/mL
  • Sterility: no growth

💡 Usage tips:

1. Radiochemical purity determined by TLC or HPLC.

2. Lu-177m impurity controlled by gamma spectrometry.

3. Synthesis usually performed on automatic modules or manually using kits.

4. Drug is stable for several days due to strong DOTA/HBED-CC complex.

5. Lu-177 emits gamma quanta 208 and 113 keV, allowing post-therapeutic imaging.

⚠️ Note: Lu-177 PSMA represents successful theranostics example (therapy + diagnostics). Quality control here is critical as error in dosing or purity can lead either to treatment inefficacy or serious toxicity to salivary glands, kidneys and bone marrow.

input.csv

BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent
LU177-PSMA-THER-2026-001,99.2,0.4,0.02,50.0,5.0,80.0,5.0,0,7.4,99.99,0.0003
LU177-PSMA-THER-2026-002,97.5,1.8,0.08,45.0,4.8,150.0,15.0,0,7.0,99.95,0.0008
LU177-PSMA-THER-2026-003,92.0,4.5,0.2,30.0,6.2,550.0,40.0,1,6.0,99.60,0.0020

URS & FS — user requirements and functional specification

URS — User Requirements Specification

  • The utility shall accept input.csv with these mandatory columns: BatchNumber, RadiochemicalPurityPercent, FreeLutetiumPercent, PrecursorPercent, SpecificActivityGBq_per_mg, pH, ResidualSolventsPPM, EndotoxinsEU_per_mL, SterilityTest, ActivityGBq, RadionuclidicPurityPercent, Lu177mImpurityPercent.
  • Each row shall be processed as a separate batch or record identified by BatchNumber.
  • Before evaluation, the utility shall validate the CSV structure, mandatory values, numeric fields and allowed text values.
  • Rules and limits shall be applied to every parameter in the input row.
  • Critical violations identified in the supplied description shall set the record result to FAIL.
  • Each row shall receive an overall PASS, WARNING or FAIL status with the triggered rules.
  • An invalid row shall not receive PASS.
  • output.json shall contain source values, applied limits, individual check results and errors.
  • The same input and the same rule profile shall produce the same result.

FS — Functional Specification

  1. Run Lu177PSMATherapyQualityChecker.exe in demonstration mode or with input.csv output.json arguments.
  2. Read UTF-8 CSV and verify the exact set of mandatory columns.
  3. Convert row values to numeric and text types.
  4. Apply the rules defined in the approved version or configuration profile.
  5. Generate individual check results and derive the overall status from the most severe violation.
  6. Write machine-readable output.json.
  7. Structural and type errors shall be reported explicitly and shall not be masked by a successful status.

Complete input.csv example

BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent
LU177-PSMA-THER-2026-001,99.2,0.4,0.02,50.0,5.0,80.0,5.0,0,7.4,99.99,0.0003
LU177-PSMA-THER-2026-002,97.5,1.8,0.08,45.0,4.8,150.0,15.0,0,7.0,99.95,0.0008
LU177-PSMA-THER-2026-003,92.0,4.5,0.2,30.0,6.2,550.0,40.0,1,6.0,99.60,0.0020

Purpose of the supplied test rows

  • The first row contains values consistent with the criteria stated in the supplied description.
  • The second row contains values closer to the limits or moderate deviations.
  • The third row contains clear deviations for negative-result testing.

Minimum output.json structure

{
  "utility": "Lu177PSMATherapyQualityChecker",
  "source": "input.csv",
  "results": [
    {
      "batchNumber": "BATCH-001",
      "status": "PASS",
      "checks": [
        {
          "parameter": "ParameterName",
          "value": 0,
          "limit": "configured rule",
          "status": "PASS"
        }
      ],
      "errors": []
    }
  ]
}

Minimum OQ scenarios

  • Process the complete supplied input.csv.
  • Remove a mandatory column and confirm a contract error.
  • Provide text instead of a numeric value and confirm a type error.
  • Test values directly on the configured limits.
  • Repeat the run with the same input and confirm an identical result.

Before operational use

  • Reconcile rules and limits with the approved specification, methods and SOP.
  • Fix the executable version and rule-profile version.
  • Retain the source CSV together with the generated JSON.

Included in packages

PetRad QC Suite

A specialised utility package for radiopharmaceutical quality control: PET, SPECT, therapeutic radionuclides, generators and decay calculations.

Open

PetRad3: expanded PET/SPECT and radiopharmaceutical QC package

A curated suite for PET/SPECT radiopharmaceuticals, generator and cyclotron radionuclides, labelled compounds, radiochemical purity, breakthrough, sterility and endotoxin control.

Open

Radioligand & Theranostics Expansion QC Suite

Radioligand & Theranostics Expansion QC Suite: FUZKK utility package for CSV→JSON QC checks with EU-first limit priority.

Open

Radiopharmaceutical Diagnostics and Therapy QC Suite

36 utilities for clinically oriented radiopharmaceutical and workflow quality control: PET/SPECT tracers, the Tc-99m renal workflow, PRRT, PSMA therapy, targeted alpha therapy, radioembolization, bone-pain palliation, immuno-PET and generator-based radionuclide control.

Open

RPH isotope family: beta-emitting therapy

Lu-177, Y-90, Ho-166, Re-188, Sm-153, Sr-89, P-32, Cu-67 and Tb-161.

Open

RPH organ/system: bone and musculoskeletal

Bone scintigraphy, MDP/PYP, marrow, bone-pain palliation, skeletal metastases and radiosynovectomy.

Open

RPH organ/system: hepatobiliary and GI

HIDA, mebrofenin, gallbladder, gastric emptying, GI transit, bleeding and liver/spleen imaging.

Open

RPH organ/system: oncology and theranostics

Tumour imaging, PSMA/FAPI/receptor tracers, immuno-PET, targeted radionuclide therapy and radioembolization.

Open

RPH organ/system: renal and urinary

Renography, GFR/ERPF, renal uptake, DMSA/MAG3/DTPA and bladder-related workflows.

Open

RPH use case: radionuclide therapy and theranostics

Lu-177, Ac-225, Ra-223, Y-90, Ho-166, Sm-153, Sr-89, Re-188, Tb-161, I-131 and other therapeutic radiopharmaceuticals: activity, purity, free metal, daughters and toxicological constraints.

Open

RPH workflow: generators and isotope purity

Generator eluate, breakthrough, radionuclidic purity, isotope mix and starting radionuclides.

Open

RPH workflow: imaging QC and quantitative interpretation

Acquisition, uptake, clearance, perfusion, transit, ejection fraction, segmentation and quantitative imaging.

Open

RPH workflow: product release QC

Assay, purity, sterility, endotoxins, pH, impurities, appearance and batch-release checks.

Open

RPH workflow: stability, storage, decay and waste

Kinetic stability, shelf life, decay correction, expiry, storage, trend and radioactive waste.

Open

RPH workflow: synthesis, labelling and kit reconstitution

Radiolabelling, synthesis, chelation, reducing agent, pH/stoichiometry and kit preparation.

Open

RPH: combined radiopharmaceutical QC package

RPH combines PetRad, PetRad2 and PetRad3 into one umbrella package for PET/SPECT, therapeutic radionuclides, generators, labelled compounds, decay calculations, sterility, endotoxins and radiochemical/radionuclidic purity.

Open